News

ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked Paradise (percutaneous renal denervation system) ultrasound platform, which is...

April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment...

Internet-based telemedicine systems appear to lead to more appropriate and effective pharmacotherapy, better blood pressure control and an overall reduction in cardiovascular risk compared to...

February 29, 2012 — Vessix Vascular Inc. announced initial patient treatments in the international multi-center Reduce-HTN renal denervation clinical study for uncontrolled hypertension.

PARADISE

February 20, 2012 — ReCor Medical announced that its Paradise percutaneous ultrasound renal denervation system for achieving rhas received the CE mark. Paradise is designed to treat patients with...

February 15, 2012 — Vessix Vascular Inc., developer of a novel percutaneous radiofrequency (RF) balloon catheter technology, announced that it will make its first detailed public presentation of...

February 15, 2012 — Medtronic Inc. announced the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s Symplicity renal denervation system across...

October 26, 2011 — Medtronic Inc. announced the start of SYMPLICITY HTN-3, the company’s United States clinical trial of the Symplicity Renal Denervation System for treatment-resistant...

August 10, 2011 – The U.S. Food and Drug Administration (FDA) has approved Abbott’s RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries...

August 2, 2011 – The U.S. Food and Drug Administration recently cleared Abbott Vascular’s RX Herculink Elite Renal Stent System. The balloon-expandable, cobalt chromium, laser-cut stent is used to...

July 14, 2011 — The U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the U.S. clinical trial of renal denervation with the Symplicity catheter...

June 14, 2011 – New performance measures for adults with coronary artery disease (CAD) and hypertension were released today by the American College of Cardiology Foundation (ACCF), the American Heart...
May 19, 2011 - Results from a study validating Cheetah Medical's noninvasive NICOM system specifically for use in patients with pulmonary hypertension were presented Wednesday, May 18th, at the 2011...
May 6, 2011 – A substance secreted by the heart that is associated with congestive heart failure and renal failure is not predictive of reduction in systolic blood pressure in patients treated with...

April 21, 2011 – A new angiotensin II receptor blocker (ARB) has been approved by the U.S. Food and Drug Administration (FDA) to treat hypertension, or high blood pressure. Edarbi (azilsartan...

March 30, 2011 – Interventional radiologists have completed the first human randomized controlled trial of therapeutic renal denervation, or RDN. RDN is a procedure that uses a catheter-based...

March 18, 2011 – Researchers have found a link between high blood pressure and a greater drop in average walking speeds in older adults, according to results from a new study. The drop seems to...

March 11, 2011 – Sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, has another possible use – helping children and young adults with congenital heart disease to...

March 8, 2011 – The U.S. Food and Drug Administration (FDA) announced monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), made by Gilead Sciences....

March 1, 2011 – The U.S. Food and Drug Administration (FDA) approved azilsartan medoxomil to treat high blood pressure (hypertension) in adults. Azilsartan medoxomil, also known as Edarbi, is made...